Continuous lenalidomide treatment for newly diagnosed multiple myeloma

Antonio Palumbo, Roman Hajek, Michel Delforge, Martin Kropff, Maria Teresa Petrucci, John Catalano, Heinz Gisslinger, Wiesław Wiktor-Jȩdrzejczak, Mamia Zodelava, Katja Weisel, Nicola Cascavilla, Genadi Iosava, Michele Cavo, Janusz Kloczko, Joan Bladé, Meral Beksac, Ivan Spicka, Torben Plesner, Joergen Radke, Christian LangerDina Ben Yehuda, Alessandro Corso, Lindsay Herbein, Zhinuan Yu, Jay Mei, Christian Jacques, Meletios A. Dimopoulos

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone- lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide (MPR) or melphalan-prednisone (MP) followed by placebo in patients 65 years of age or older with newly diagnosed multiple myeloma. METHODS: We randomly assigned patients who were ineligible for transplantation to receive MPR-R (nine 4-week cycles of MPR followed by lenalidomide maintenance therapy until a relapse or disease progression occurred [152 patients]) or to receive MPR (153 patients) or MP (154 patients) without maintenance therapy. The primary end point was progression-free survival. RESULTS: The median follow-up period was 30 months. The median progression-free survival was significantly longer with MPR-R (31 months) than with MPR (14 months; hazard ratio, 0.49; P

Original languageEnglish
Pages (from-to)1759-1769
Number of pages11
JournalNew England Journal of Medicine
Volume366
Issue number19
DOIs
Publication statusPublished - May 10 2012

Fingerprint

Melphalan
Multiple Myeloma
Prednisone
Therapeutics
Disease-Free Survival
lenalidomide
Multicenter Studies
Disease Progression
Transplantation
Placebos
Maintenance
Recurrence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Palumbo, A., Hajek, R., Delforge, M., Kropff, M., Petrucci, M. T., Catalano, J., ... Dimopoulos, M. A. (2012). Continuous lenalidomide treatment for newly diagnosed multiple myeloma. New England Journal of Medicine, 366(19), 1759-1769. https://doi.org/10.1056/NEJMoa1112704

Continuous lenalidomide treatment for newly diagnosed multiple myeloma. / Palumbo, Antonio; Hajek, Roman; Delforge, Michel; Kropff, Martin; Petrucci, Maria Teresa; Catalano, John; Gisslinger, Heinz; Wiktor-Jȩdrzejczak, Wiesław; Zodelava, Mamia; Weisel, Katja; Cascavilla, Nicola; Iosava, Genadi; Cavo, Michele; Kloczko, Janusz; Bladé, Joan; Beksac, Meral; Spicka, Ivan; Plesner, Torben; Radke, Joergen; Langer, Christian; Yehuda, Dina Ben; Corso, Alessandro; Herbein, Lindsay; Yu, Zhinuan; Mei, Jay; Jacques, Christian; Dimopoulos, Meletios A.

In: New England Journal of Medicine, Vol. 366, No. 19, 10.05.2012, p. 1759-1769.

Research output: Contribution to journalArticle

Palumbo, A, Hajek, R, Delforge, M, Kropff, M, Petrucci, MT, Catalano, J, Gisslinger, H, Wiktor-Jȩdrzejczak, W, Zodelava, M, Weisel, K, Cascavilla, N, Iosava, G, Cavo, M, Kloczko, J, Bladé, J, Beksac, M, Spicka, I, Plesner, T, Radke, J, Langer, C, Yehuda, DB, Corso, A, Herbein, L, Yu, Z, Mei, J, Jacques, C & Dimopoulos, MA 2012, 'Continuous lenalidomide treatment for newly diagnosed multiple myeloma', New England Journal of Medicine, vol. 366, no. 19, pp. 1759-1769. https://doi.org/10.1056/NEJMoa1112704
Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. New England Journal of Medicine. 2012 May 10;366(19):1759-1769. https://doi.org/10.1056/NEJMoa1112704
Palumbo, Antonio ; Hajek, Roman ; Delforge, Michel ; Kropff, Martin ; Petrucci, Maria Teresa ; Catalano, John ; Gisslinger, Heinz ; Wiktor-Jȩdrzejczak, Wiesław ; Zodelava, Mamia ; Weisel, Katja ; Cascavilla, Nicola ; Iosava, Genadi ; Cavo, Michele ; Kloczko, Janusz ; Bladé, Joan ; Beksac, Meral ; Spicka, Ivan ; Plesner, Torben ; Radke, Joergen ; Langer, Christian ; Yehuda, Dina Ben ; Corso, Alessandro ; Herbein, Lindsay ; Yu, Zhinuan ; Mei, Jay ; Jacques, Christian ; Dimopoulos, Meletios A. / Continuous lenalidomide treatment for newly diagnosed multiple myeloma. In: New England Journal of Medicine. 2012 ; Vol. 366, No. 19. pp. 1759-1769.
@article{8dd267e7696e412a8a77a516dab81462,
title = "Continuous lenalidomide treatment for newly diagnosed multiple myeloma",
abstract = "BACKGROUND: Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone- lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide (MPR) or melphalan-prednisone (MP) followed by placebo in patients 65 years of age or older with newly diagnosed multiple myeloma. METHODS: We randomly assigned patients who were ineligible for transplantation to receive MPR-R (nine 4-week cycles of MPR followed by lenalidomide maintenance therapy until a relapse or disease progression occurred [152 patients]) or to receive MPR (153 patients) or MP (154 patients) without maintenance therapy. The primary end point was progression-free survival. RESULTS: The median follow-up period was 30 months. The median progression-free survival was significantly longer with MPR-R (31 months) than with MPR (14 months; hazard ratio, 0.49; P",
author = "Antonio Palumbo and Roman Hajek and Michel Delforge and Martin Kropff and Petrucci, {Maria Teresa} and John Catalano and Heinz Gisslinger and Wiesław Wiktor-Jȩdrzejczak and Mamia Zodelava and Katja Weisel and Nicola Cascavilla and Genadi Iosava and Michele Cavo and Janusz Kloczko and Joan Blad{\'e} and Meral Beksac and Ivan Spicka and Torben Plesner and Joergen Radke and Christian Langer and Yehuda, {Dina Ben} and Alessandro Corso and Lindsay Herbein and Zhinuan Yu and Jay Mei and Christian Jacques and Dimopoulos, {Meletios A.}",
year = "2012",
month = "5",
day = "10",
doi = "10.1056/NEJMoa1112704",
language = "English",
volume = "366",
pages = "1759--1769",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "19",

}

TY - JOUR

T1 - Continuous lenalidomide treatment for newly diagnosed multiple myeloma

AU - Palumbo, Antonio

AU - Hajek, Roman

AU - Delforge, Michel

AU - Kropff, Martin

AU - Petrucci, Maria Teresa

AU - Catalano, John

AU - Gisslinger, Heinz

AU - Wiktor-Jȩdrzejczak, Wiesław

AU - Zodelava, Mamia

AU - Weisel, Katja

AU - Cascavilla, Nicola

AU - Iosava, Genadi

AU - Cavo, Michele

AU - Kloczko, Janusz

AU - Bladé, Joan

AU - Beksac, Meral

AU - Spicka, Ivan

AU - Plesner, Torben

AU - Radke, Joergen

AU - Langer, Christian

AU - Yehuda, Dina Ben

AU - Corso, Alessandro

AU - Herbein, Lindsay

AU - Yu, Zhinuan

AU - Mei, Jay

AU - Jacques, Christian

AU - Dimopoulos, Meletios A.

PY - 2012/5/10

Y1 - 2012/5/10

N2 - BACKGROUND: Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone- lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide (MPR) or melphalan-prednisone (MP) followed by placebo in patients 65 years of age or older with newly diagnosed multiple myeloma. METHODS: We randomly assigned patients who were ineligible for transplantation to receive MPR-R (nine 4-week cycles of MPR followed by lenalidomide maintenance therapy until a relapse or disease progression occurred [152 patients]) or to receive MPR (153 patients) or MP (154 patients) without maintenance therapy. The primary end point was progression-free survival. RESULTS: The median follow-up period was 30 months. The median progression-free survival was significantly longer with MPR-R (31 months) than with MPR (14 months; hazard ratio, 0.49; P

AB - BACKGROUND: Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone- lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide (MPR) or melphalan-prednisone (MP) followed by placebo in patients 65 years of age or older with newly diagnosed multiple myeloma. METHODS: We randomly assigned patients who were ineligible for transplantation to receive MPR-R (nine 4-week cycles of MPR followed by lenalidomide maintenance therapy until a relapse or disease progression occurred [152 patients]) or to receive MPR (153 patients) or MP (154 patients) without maintenance therapy. The primary end point was progression-free survival. RESULTS: The median follow-up period was 30 months. The median progression-free survival was significantly longer with MPR-R (31 months) than with MPR (14 months; hazard ratio, 0.49; P

UR - http://www.scopus.com/inward/record.url?scp=84860744403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860744403&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1112704

DO - 10.1056/NEJMoa1112704

M3 - Article

C2 - 22571200

AN - SCOPUS:84860744403

VL - 366

SP - 1759

EP - 1769

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 19

ER -